The complete response for Brukinsa, or the absence of all detectable tumors, reached 59 percent among patients with relapsed or refractory MCL, and that for Calquence and Imbruvica were 40 percent and 21 percent respectively.
未经许可，严禁转发。QQ交流群：688169419